scispace - formally typeset
Open AccessJournal ArticleDOI

Small-Molecule Inhibitors That Target Protein–Protein Interactions in the RAD51 Family of Recombinases

Reads0
Chats0
TLDR
This study reports the development of indole‐based fragments that bind in a shallow surface pocket of a humanised surrogate of RAD51, an ATP‐dependent recombinase that plays a key role in the repair of double‐strand DNA breaks.
Abstract
The development of small molecules that inhibit protein–protein interactions continues to be a challenge in chemical biology and drug discovery. Herein we report the development of indole-based fragments that bind in a shallow surface pocket of a humanised surrogate of RAD51. RAD51 is an ATP-dependent recombinase that plays a key role in the repair of double-strand DNA breaks. It both self-associates, forming filament structures with DNA, and interacts with the BRCA2 protein through a common “FxxA” tetrapeptide motif. We elaborated previously identified fragment hits that target the FxxA motif site and developed small-molecule inhibitors that are approximately 500-fold more potent than the initial fragments. The lead compounds were shown to compete with the BRCA2-derived Ac-FHTA-NH2 peptide and the self-association peptide of RAD51, but they had no effect on ATP binding. This study is the first reported elaboration of small-molecular-weight fragments against this challenging target.

read more

Citations
More filters
Journal ArticleDOI

Drug Discovery Today

TL;DR: A wide range of new lead finding and lead optimization opportunities result from novel screening methods by NMR, which are the topic of this review article.
Journal ArticleDOI

Small molecules, big targets: drug discovery faces the protein–protein interaction challenge

TL;DR: The research leading to breakthroughs in PPI inhibition is described and the existence of groups of structurally related PPIs within the PPI target class is highlighted to illustrate the research strategies that have proved most useful.
Journal ArticleDOI

Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.

TL;DR: A thorough understanding of DDR pathway complexities must be combined with strategies and lessons learned from the successful registration of PARP inhibitors in order to fully exploit the potential of DDR inhibitors and to ensure their long-term clinical success.
Journal ArticleDOI

Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia.

TL;DR: This Perspective explores many of the theoretical, practical, and strategic considerations that occur within FBDD programs, including the optimal size, complexity, physicochemical profile, and shape profile of fragments in FBDD libraries, as well as compound storage, evaluation, and screening technologies.
Journal ArticleDOI

Small-Molecule Inhibitors Targeting DNA Repair and DNA Repair Deficiency in Research and Cancer Therapy.

TL;DR: This review discusses several successful campaigns to identify and leverage small-molecule inhibitors of the DNA repair proteins, from PARP1, a paradigm case for clinically successful small- molecule inhibitor, to coveted new targets, such as RAD51 recombinase, RAD52 DNA repair protein, MRE11 nuclease, and WRN DNA helicase.
References
More filters
Journal ArticleDOI

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.

TL;DR: In this article, the authors identify potent and selective small-molecule antagonists of MDM2 and confirm their mode of action through the crystal structures of complexes, leading to cell cycle arrest, apoptosis, and growth inhibition of human tumor xenografts.
Journal ArticleDOI

The influence of drug-like concepts on decision-making in medicinal chemistry

TL;DR: Analysis of recent trends reveals that the physical properties of molecules that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compounds in clinical development.
Journal ArticleDOI

The atomic structure of protein-protein recognition sites.

TL;DR: In this paper, the authors performed an analysis of the recognition sites seen in 75 protein-protein complexes of known three-dimensional structure: 24 protease-inhibitor, 19 antibody-antigen and 32 other complexes, including nine enzymeinhibitors and 11 that are involved in signal transduction.
Related Papers (5)